Search Results for: TSC1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
MBP myelin basic protein
  • EGR2 and SOX10-mediated initiation of Schwann cell myelination
MSANTD3 Myb/SANT DNA binding domain containing 3
MSN moesin
  • Recycling pathway of L1
  • Recycling pathway of L1
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
  • Sensory processing of sound by inner hair cells of the cochlea
  • Sensory processing of sound by outer hair cells of the cochlea
  • Signaling by ALK fusions and activated point mutants
MT-ND1 NADH dehydrogenase subunit 1
  • Mitochondrial translation termination
  • Respiratory electron transport
  • Complex I biogenesis
  • Mitochondrial protein degradation
  • NADH
  • Methoxyflurane
  • Halothane
  • Desflurane
  • Sevoflurane
  • N-Formylmethionine
  • Phenethyl Isothiocyanate
  • Leber optic atrophy; Leber hereditary optic atrophy (LHON)
MYC MYC proto-oncogene, bHLH transcription factor
  • Transcription of E2F targets under negative control by DREAM complex
  • Signaling by ALK
  • NOTCH1 Intracellular Domain Regulates Transcription
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • MAPK6/MAPK4 signaling
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • TFAP2 (AP-2) family regulates transcription of cell cycle factors
  • RUNX3 regulates WNT signaling
  • Estrogen-dependent gene expression
  • Transcriptional regulation of granulopoiesis
  • Regulation of CDH1 mRNA translation by microRNAs
  • Regulation of NFE2L2 gene expression
  • Regulation of PD-L1(CD274) transcription
  • Acetylsalicylic acid
  • Dimethyl sulfoxide
  • Doconexent
  • Nadroparin
  • Penile cancer
  • Breast cancer
  • Laryngeal cancer
  • Oral cancer
  • Multiple myeloma
  • Kaposi's sarcoma
  • Ovarian cancer
  • Choriocarcinoma
  • Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
  • Burkitt lymphoma
  • Small cell lung cancer
  • Osteosarcoma
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
MYLIP myosin regulatory light chain interacting protein
  • VLDLR internalisation and degradation
  • NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake
  • Antigen processing: Ubiquitination & Proteasome degradation
MYOZ3 myozenin 3
NECAB2 N-terminal EF-hand calcium binding protein 2
NEFL neurofilament light chain
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
NF2 NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor
  • Regulation of actin dynamics for phagocytic cup formation
  • RHO GTPases activate PAKs
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Malignant pleural mesothelioma
NINL ninein like
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • AURKA Activation by TPX2
NKD2 NKD inhibitor of Wnt signaling pathway 2
NRBF2 nuclear receptor binding factor 2
PATL1 PAT1 homolog 1, processing body mRNA decay factor
  • mRNA decay by 5' to 3' exoribonuclease
  • mRNA decay by 5' to 3' exoribonuclease
PATZ1 POZ/BTB and AT hook containing zinc finger 1
PHLDB1 pleckstrin homology like domain family B member 1
PICK1 protein interacting with PRKCA 1
  • Cell surface interactions at the vascular wall
  • Trafficking of GluR2-containing AMPA receptors
PITX1 paired like homeodomain 1
  • Congenital clubfoot; Congenital talipes equinovarus
PLK1 polo like kinase 1
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Polo-like kinase mediated events
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Phosphorylation of the APC/C
  • Phosphorylation of Emi1
  • Condensation of Prophase Chromosomes
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • Regulation of PLK1 Activity at G2/M Transition
  • Activation of NIMA Kinases NEK9, NEK6, NEK7
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • Mitotic Metaphase/Anaphase Transition
  • Mitotic Telophase/Cytokinesis
  • Cyclin A/B1/B2 associated events during G2/M transition
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • EML4 and NUDC in mitotic spindle formation
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol
  • 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide
  • 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
  • 1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea
  • Wortmannin
  • Fostamatinib
  • Volasertib
PLK2 polo like kinase 2
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • CD163 mediating an anti-inflammatory response
  • NPAS4 regulates expression of target genes
  • Fostamatinib

Page 6 out of 9 pages